Phase 2 Study of ADX-038 for Complement-Mediated Kidney Disease
This Phase 2 study is testing ADX-038, a siRNA duplex oligonucleotide, in adults with complement-mediated kidney diseases like IgA nephropathy (IgAN), C3 glomerulopathy (C3G), and IC-MPGN. The study aims to understand how safe ADX-038 is and how well your body tolerates it over 36 months. You may be able to join if you are 18 or older, have active kidney disease with an eGFR (a measure of kidney function) of 30 mL/min/1.73m2 or higher, and have a confirmed diagnosis of IgAN, C3G, or IC-MPGN from a kidney biopsy. The study is planning to enroll 45 participants, but its current recruitment status is unclear.
- Study design
- This is a Phase 2 interventional study planning to enroll 45 participants. It will assess two different dose levels of ADX-038.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for the length of the study, which is 36 months, to evaluate the safety and tolerability of ADX-038.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
At a glance
Conditions
Where it's being run
34 sites across 18 statesStudy leadership
- Arezoo Mirad, MD · STUDY_DIRECTOR · ADARx Pharmaceuticals, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Evaluate the safety and tolerability of ADX-038Length of study - 36 months
Incidence and severity of TEAEs